N6-Methyladenosine-binding proteins suppress HIV-1 infectivity and viral production. 2018

Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
From the Center for Retrovirus Research, Department of Veterinary Biosciences, Ohio State University, Columbus, Ohio 43210.

The internal N6-methyladenosine (m6A) modification of cellular mRNA regulates post-transcriptional gene expression. The YTH domain family proteins (YTHDF1-3 or Y1-3) bind to m6A-modified cellular mRNAs and modulate their metabolism and processing, thereby affecting cellular protein translation. We previously reported that HIV-1 RNA contains the m6A modification and that Y1-3 proteins inhibit HIV-1 infection by decreasing HIV-1 reverse transcription activity. Here, we investigated the mechanisms of Y1-3-mediated inhibition of HIV-1 infection in target cells and the effect of Y1-3 on viral production levels in virus-producing cells. We found that Y1-3 protein overexpression in HIV-1 target cells decreases viral genomic RNA (gRNA) levels and inhibits both early and late reverse transcription. Purified recombinant Y1-3 proteins preferentially bound to the m6A-modified 5' leader sequence of gRNA compared with its unmodified RNA counterpart, consistent with the strong binding of Y1-3 proteins to HIV-1 gRNA in infected cells. HIV-1 mutants with two altered m6A modification sites in the 5' leader sequence of gRNA exhibited significantly lower infectivity than WT, replication-competent HIV-1, confirming that these sites alter viral infection. HIV-1 produced from cells in which endogenous Y1, Y3, or Y1-3 proteins were knocked down singly or together had increased viral infectivity compared with HIV-1 produced in control cells. Interestingly, we found that Y1-3 proteins and HIV-1 Gag protein formed a complex with RNA in HIV-1-producing cells. Overall, these results indicate that Y1-3 proteins inhibit HIV-1 infection and provide new insights into the mechanisms by which the m6A modification of HIV-1 RNA affects viral replication.

UI MeSH Term Description Entries
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D014771 Virion The infective system of a virus, composed of the viral genome, a protein core, and a protein coat called a capsid, which may be naked or enclosed in a lipoprotein envelope called the peplos. Virus Particle,Viral Particle,Viral Particles,Particle, Viral,Particle, Virus,Particles, Viral,Particles, Virus,Virions,Virus Particles
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D015683 Gene Products, gag Proteins coded by the retroviral gag gene. The products are usually synthesized as protein precursors or POLYPROTEINS, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. gag is short for group-specific antigen. Viral gag Proteins,gag Antigen,gag Gene Product,gag Gene Products,gag Polyproteins,gag Protein,gag Viral Proteins,Gene Product, gag,Retroviral Antigen gag Protein,gag Antigens,gag Gene Related Protein,gag Polyprotein,Antigen, gag,Antigens, gag,Polyprotein, gag,Polyproteins, gag,Protein, gag,Proteins, Viral gag,Proteins, gag Viral,Viral Proteins, gag,gag Proteins, Viral
D016601 RNA-Binding Proteins Proteins that bind to RNA molecules. Included here are RIBONUCLEOPROTEINS and other proteins whose function is to bind specifically to RNA. Double-Stranded RNA-Binding Protein,Double-Stranded RNA-Binding Proteins,ds RNA-Binding Protein,RNA-Binding Protein,ds RNA-Binding Proteins,Double Stranded RNA Binding Protein,Double Stranded RNA Binding Proteins,Protein, Double-Stranded RNA-Binding,Protein, ds RNA-Binding,RNA Binding Protein,RNA Binding Proteins,RNA-Binding Protein, Double-Stranded,RNA-Binding Protein, ds,RNA-Binding Proteins, Double-Stranded,ds RNA Binding Protein

Related Publications

Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
March 2019, The Journal of biological chemistry,
Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
January 2018, Frontiers in microbiology,
Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
January 2019, Frontiers in microbiology,
Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
August 2017, Methods (San Diego, Calif.),
Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
May 2021, Trends in biochemical sciences,
Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
May 2017, Mucosal immunology,
Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
May 2017, Mucosal immunology,
Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
July 1990, AIDS research and human retroviruses,
Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
September 2023, Nature cell biology,
Wuxun Lu, and Nagaraja Tirumuru, and Corine St Gelais, and Pratibha C Koneru, and Chang Liu, and Mamuka Kvaratskhelia, and Chuan He, and Li Wu
August 2019, RNA biology,
Copied contents to your clipboard!